Le Lézard
Classified in: Health, Science and technology

Global Synthetic Artificial Blood Vessels Market (2021 to 2026) - Featuring Humacyte, LeMaitre Vascular and Cook Medical Among Others - ResearchAndMarkets.com


The "Synthetic Artificial Blood Vessels Market - Global Industry Analysis (2018 - 2020) - Growth Trends and Market Forecast (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

According to the author, the global synthetic artificial blood vessels market is expected to be worth US$319.4 Mn by 2026 from US$296.8 Mn in 2021. During the forecast years of 2021 and 2026, the global market for synthetic artificial blood vessels is poised to register a CAGR of 5.7%.

The global synthetic artificial blood vessels market is slated to see a steadily rising demand as cardiovascular diseases (CVDs) continue to be on the rise. About 85,000 vascular reconstruction surgeries are performed globally every year. Furthermore, CVDs that lead to narrowing or blockage of blood vessels remains the leading cause of death. These glaring statistics are expected to drive the demand for synthetic artificial blood vessels are sophistication in technology makes them a life-saving tool.

Companies Mentioned

Key Insights Into Global Synthetic Artificial Blood Vessels Market:

Investments in Research and Development Offer Superior Products

The ongoing research and development to make superior synthetic artificial blood vessels are expected to introduce better outcomes for patients in the coming years. The bioengineered blood vessels that can be successfully implanted into human beings have become self-healing tubes that carry blood effortlessly, allowing better quality of life.

The report indicates that research could open doors to the application of synthetic blood vessels in complicated procedures such as wound healing and high-risk surgeries. Synthetic blood vessels are expected to play a critical role in giving patients on haemodialysis a new lease on life during the forecast period. As renal complications remain on the rise, these bioengineered vessels will find a lucrative area of application.

North America to Create Lucrative Opportunities for Synthetic Blood Vessels Market

According to the author, the global synthetic blood vessels market will be dominated by North America. By the end of 2026, North America will reach a valuation of US$120.9 Mn. The growing research and development of biomaterials, technological advancements and quick uptake, well-established diagnostic procedures, and reimbursement policies are expected to fuel the growth of this market during the forecast period.

Meanwhile, Europe is will a remarkable pace of growth as the region has a considerable size of the ageing population who are likely to need synthetic blood vessels as complications due to kidney failures, aortic disease, and other health issues arise.

Key Topics Covered:

1. Executive Summary

2. Market Overview

2.1. Market Definitions and Segmentations

2.2. Market Dynamics

2.2.1. Market Drivers

2.2.2. Market Restraints

2.3. Synthetic Polymers

2.4. Polymer Surface Modifications

3. Global Synthetic Artificial Blood Vessels Market Outlook, 2018 - 2026

3.1. Global Synthetic Artificial Blood Vessels Market Outlook, By Polymer, 2018 - 2026

3.2. Global Synthetic Artificial Blood Vessels Market Outlook, By Application, 2018 - 2026

3.3. Global Synthetic Artificial Blood Vessels Market Outlook, End user, 2018 - 2026

3.4. Global Synthetic Artificial Blood Vessels Market Outlook, By Region, 2018 - 2026

4. North America Synthetic Artificial Blood Vessels Market Outlook, 2018 - 2026

5. Europe Synthetic Artificial Blood Vessels Market Outlook, 2018 - 2026

6. Asia Pacific Synthetic Artificial Blood Vessels Market Outlook, 2018 - 2026

7. Rest of World Synthetic Artificial Blood Vessels Market Outlook, 2018 - 2026

8. Competitive Landscape

8.1. Market Share Analysis, 2021

8.2. Company Profiles

9. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/pijcv5


These press releases may also interest you

at 08:15
Guardant Health, Inc. , a leading precision oncology company, announced today it will present new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago. Among the 19 abstracts are oral presentations...

at 08:15
The "Royalty Rates for Pharmaceuticals & Biotechnology, 9th Edition" report has been added to ResearchAndMarkets.com's offering. Royalty Rates for Pharmaceuticals & Biotechnology features more real-deal royalty rates, license fees, and milestone...

at 08:15
International Evidence of Ritual Abuse Conference The conference was an excellent conference again this year. Attendees included participants from Europe, Canada, and the US. The Survivorship Ritual Abuse and Mind Control 2022 Conference The...

at 08:15
For both employers and employees, unchecked emotions can complicate relationships and routines at work. Supportiv, the on-demand peer-to-peer emotional support service, releases a new collection of mental health resources to help understand and...

at 08:10
Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar...

at 08:10
Seagen Inc. today announced positive topline results from the pivotal phase 2 MOUNTAINEER clinical trial investigating TUKYSA® (tucatinib) in combination with trastuzumab in patients with previously treated HER2-positive metastatic colorectal cancer...



News published on 21 january 2022 at 10:20 and distributed by: